Maxim Group analyst Michael Okunewitch maintained a Buy rating on Longeveron (LGVN – Research Report) yesterday. The company’s shares opened today at $0.55.
Okunewitch covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Mediwound, and Citius Pharmaceuticals. According to TipRanks, Okunewitch has an average return of -15.7% and a 25.25% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Longeveron with a $6.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
LGVN market cap is currently $13.69M and has a P/E ratio of -0.52.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LGVN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Longeveron (LGVN) Company Description:
Longeveron LLC is a biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).
Read More on LGVN:
- Longeveron Reports Year-End 2023 Results and Provides Corporate Update
- LGVN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Longeveron Stockholders Approve Reverse Split and Charter Amendment
- Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024
- Longeveron files to sell 1.45M shares of Class A common stock for holders
